Brief Title
Effect of Intraventricular tPA Following Aneurysmal Subarachnoid Hemorrhage
Official Title
Effect of Intraventricular tPA Following Aneurysmal Subarachnoid Hemorrhage
Brief Summary
This study will evaluate the hypothesis that the administration of intraventricular tPA reduces the rates of cerebral vasospasm and ventriculoperitoneal shunt-dependent hydrocephalus in patients with aneurysmal subarachnoid hemorrhage.
Study Phase
Phase 1/Phase 2
Study Type
Interventional
Primary Outcome
Composite Primary Outcome
Secondary Outcome
Rate of new intracranial hemorrhage
Condition
Subarachnoid Hemorrhage
Intervention
Tissue Plasminogen Activator
Study Arms / Comparison Groups
Intraventricular tPA
Description: Tissue Plasminogen Activator (tPA) Dose: 1 mg Q8 hr x 12 doses, or until blood is cleared from the ventricles and cisterns Adminstration: Intraventricular; via previously placed external ventricular drain
Publications
* Includes publications given by the data provider as well as publications identified by National Clinical Trials Identifier (NCT ID) in Medline.
Recruitment Information
Recruitment Status
Drug
Estimated Enrollment
0
Start Date
March 2015
Completion Date
September 2016
Primary Completion Date
September 2016
Eligibility Criteria
Inclusion Criteria: - Age greater than 18 years old. - SAH due to aneurysm, as determined by CT angiogram or cerebral angiogram. - Modified Fisher (mF) grade 3 or 4 SAH, defined as thick cisternal blood without (grade 3) or with (grade 4) intraventrciular blood. - Exclusion of the aneurysm from the parent circulation by endovascular embolization (Raymond class I or II) within 48 hours of ictus. - Ventriculostomy placement must occur prior to randomization. - Informed consent obtained from the patient or patient's decision maker Exclusion Criteria: - Determination by treating physician(s) that no ventriculostomy is needed. - Presence of intrinsic clotting disorders (e.g. due to hepatic failure, nephrotic syndrome, etc). Subjects whose pharmacologic anticoagulation is reversed, as determined by PT/INR, PTT within our institution's normal range, will be permitted to participate in this study. - Presence of significant anemia, defined as hemoglobin < 8 gm/dL. - Patients who undergo endovascular techniques requiring post-operative dual anti-platelet therapy. - Residual aneurysm sac filling (Raymond class III occlusion). - Aneurysm or vessel perforation during the endovascular procedure. - Presence of craniectomy. - Significant neurologic disability prior to the onset of SAH. - Determination that administration of tPA/placebo cannot be initiated within 72 hours of symptom onset. - Presence of untreated intracranial aneurysms larger than 3mm on CT angiography or cerebral angiogram.
Gender
All
Ages
18 Years - N/A
Accepts Healthy Volunteers
No
Contacts
Stephan Munich, MD, ,
Location Countries
United States
Location Countries
United States
Administrative Informations
NCT ID
NCT01878136
Organization ID
13011803
Responsible Party
Principal Investigator
Study Sponsor
Rush University Medical Center
Study Sponsor
Stephan Munich, MD, Principal Investigator, Rush University Medical Center, Department of Neurosurgery
Verification Date
November 2015